Arcadis NV Quote - ARCAD | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
Europe
EU
Arcadis NV (ARCAD) Share Price

Arcadis NV (ARCAD)

49.48

-0.92

(-1.83%)

Closed 24 February 3:30AM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Current Price

49.48

Bid

49.28

Offer

50.60

Volume

145,587

49.36 Day's Range 50.70

49.36 52 Week Range 66.85

Market Cap

Previous Close

50.40

Open

50.40

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

140,419

Shares Outstanding

89,411,000

Dividend Yield

-

PE Ratio

18.21

Earnings Per Share (EPS)

2.72

Revenue

5B

Net Profit

243M

Sector

Engineering Services

Industry

Engineering Services Civil

Website

www.arcadis.com

Headquarters

Amsterdam, North Holland, Nld

Founded

1888

Arcadis NV is listed in the Engineering Services sector of the Euronext with ticker ARCAD. The last closing price for Arcadis NV was 50.40 €. Over the last year, Arcadis NV shares have traded in a share price range of 49.36 € to 66.85 €.

Arcadis NV currently has 89,411,000 shares in issue. The market capitalisation of Arcadis NV is 4.51 € billion. Arcadis NV has a price to earnings ratio (PE ratio) of 18.21.

Arcadis Q4 and Full Year 2024 Results: Record earnings per share, record backlog, enhanced long term visibility

Arcadis Q4 and Full Year 2024 Results: Record earnings per share, record backlog, enhanced long term visibility PRESS RELEASE | Arcadis Fourth...

Arcadis completes share buyback program and reports final transactions

Arcadis completes share buyback program and reports final transactions Arcadis completes share buyback program and reports final transactions...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Arcadis Trading Update Q3 2024: Multi-year wins drive significant order intake, margin expansion continues

Arcadis Trading Update Q3 2024: Multi-year wins drive significant order intake, margin expansion continues PRESS RELEASE Arcadis Third Quarter...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Arcadis reports transactions under its current share buyback program

Arcadis reports transactions under its current share buyback program Arcadis reports transactions under its current share buyback program...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-4.12	-7.68656716418	53.6	53.6	49.36	176719	51.30516198	DE
4	-5.77	-10.443438914	55.25	55.5	49.36	145208	53.34340531	DE
12	-12.52	-20.1935483871	62	64.65	49.36	140419	56.55334117	DE
26	-13.62	-21.5847860539	63.1	66.85	49.36	164135	61.1191647	DE
52	-0.38	-0.76213397513	49.86	66.85	49.36	186998	60.46057892	DE
156	7.66	18.3165949307	41.82	66.85	30.84	147316	48.08686184	DE
260	25.68	107.899159664	23.8	66.85	11.91	153648	39.5866699	DE

ARCAD - Frequently Asked Questions (FAQ)

What is the current Arcadis NV share price?

The current share price of Arcadis NV is 49.48 €

How many Arcadis NV shares are in issue?

Arcadis NV has 89,411,000 shares in issue

What is the market cap of Arcadis NV?

The market capitalisation of Arcadis NV is EUR 4.51B

What is the 1 year trading range for Arcadis NV share price?

Arcadis NV has traded in the range of 49.36 € to 66.85 € during the past year

What is the PE ratio of Arcadis NV?

The price to earnings ratio of Arcadis NV is 18.21

What is the cash to sales ratio of Arcadis NV?

The cash to sales ratio of Arcadis NV is 0.88

What is the reporting currency for Arcadis NV?

Arcadis NV reports financial results in EUR

What is the latest annual turnover for Arcadis NV?

The latest annual turnover of Arcadis NV is EUR 5B

What is the latest annual profit for Arcadis NV?

The latest annual profit of Arcadis NV is EUR 243M

What is the registered address of Arcadis NV?

The registered address for Arcadis NV is GUSTAV MAHLERPLEIN 97, AMSTERDAM, NORTH HOLLAND, 1082 MS

What is the Arcadis NV website address?

The website address for Arcadis NV is www.arcadis.com

Which industry sector does Arcadis NV operate in?

Arcadis NV operates in the ENGINEERING SERVICES CIVIL sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ALSRSSirius Media	0.0158 € (59.60%)	82M
ALGLDGold By Gold	3.60 € (19.21%)	5.56k
TKTTTarkett	15.85 € (16.97%)	309.86k
GTTGaztransport Et Technigaz	155.10 € (15.92%)	578.09k
NBANovabase Sociedade Gestora De Participacoes Sociais SA	7.25 € (15.08%)	30.52k
ALCYBCybergun	0.0001 € (-50.00%)	21.7M
MLTROTroc de l Ile	2.60 € (-23.53%)	70
MLPRXParx Materials NV	0.228 € (-22.45%)	300
ALIMRImmersion	1.47 € (-22.22%)	856
ALADOAdomos	0.24 € (-20.00%)	21.32k
ATOAtos SE	0.0032 € (-5.88%)	979.37M
ALVERVergnet	0.0005 € (0.00%)	124.09M
ALSRSSirius Media	0.0158 € (59.60%)	82M
ALHPIHopium SA	0.0029 € (3.57%)	33.48M
BCPBanco Comercial Portugues SA	0.5498 € (1.63%)	28.49M

Nebuchadnezzar

Nebuchadnezzar 5 minutes ago

.0024/.0982---.0244 x100 = 2.44%

so RITE is trading 2.44% of book value of .0982 based on DDAmanda

or

.0024 divided by .031 (Book value as mentioned in filings) which = .07741 x 100 equals 7.741% of book value

Zorax

Zorax 5 minutes ago

That's the same link I used... read this part again. russia had some sort of say all along. Maybe it's the EU, but over five years ago or further back was again more requesting NATO membership by Ukraine. And russia said no. russia, hungary and even poland have stymied Ukraine since before 2014. Aft

CCSAB

CCSAB 6 minutes ago

2000% gain on exit from conservatorship????Was this posted while you were high on mama's nail polish remover?

janice shell

janice shell 7 minutes ago

Don Bongino? Trump does seem determined to wreck the country in every possible way. He wasn't kidding when he said his second term would be about "retribution".

He needs to be impeached. And convicted, this time.

CCSAB

CCSAB 8 minutes ago

You clearly have no idea what you are talking about. Put the pompoms down and check the facts fool.

Tom turtles

Tom turtles 9 minutes ago

I see a big f****** nothing...jack o f f

silkmaster

silkmaster 9 minutes ago

And yet we are still at 0.09+ pps imo.
Why is that? KT knows while we are sitting in the dark and getting a letter every end of year telling us next year will be graund breaking ...
Good luck to us...

CCSAB

CCSAB 10 minutes ago

Are you gonna look stupid pompom boy

ddls

ddls 10 minutes ago

Such helpful marketing thoughts are enjoyable to read, but a hopeless useless case in reality. 🤠

JMCK6193

JMCK6193 10 minutes ago

36-40 💪

$NXPL

Zorax

Zorax 10 minutes ago

I don't think peaceful protests are going to cut it.

CCSAB

CCSAB 13 minutes ago

Wow you gonna be a big winner with your 10 shares of FNMA! Mom's gonna be so proud of her little half wit cheerleader.

Tom turtles

Tom turtles 13 minutes ago

Excrement you mean you big turd..

tom16

tom16 13 minutes ago

Sounds like Pantera prefers the Koch's direct lithium extraction solution. Wonder what the difference is from IBAT's plant.
Could it be that theirs is not modular?

georgejjl

georgejjl 18 minutes ago

PREVENTION

EARLY TREATMENT

WITH BLARCAMESINE and/or ANAVEX 3-71

Good luck and GOD bless,

silver_bars

silver_bars 20 minutes ago

Some of my Research notes from the Jesse Livermore trading strategy .................

JESSE LIVERMORE Breakout Method EXPLAINED | Greatest SWING TRADER Ever
https://www.youtube.com/watch?v=qhoVYVGLQkk
Jack Corsellis
May 5, 2023
1 hr and 33 mins
GN;

Mauigold

Mauigold 22 minutes ago

Sorry, been busy son, what the hell is a GOLPHER?

Tom turtles

Tom turtles 23 minutes ago

Sure it is you fuccing grub...go suck a dic you t wat

silver_bars

silver_bars 25 minutes ago

I think as long as he doesn't hold any options on Gold futures, he probably wouldn't have anything to worry about in regards to disclosure or conflict-of-interest issues.

silver_bars

silver_bars 30 minutes ago

The VCP chart patterns work in any sector ... one of the main keys is to find a sector already in a uptrend, then scan the individual companies in the sector ....

Generally speaking, i don't like to jump into the market on Monday mornings .... I like to see how the markets play out o

blackcat

blackcat 33 minutes ago

Excellent! I didn't know that/

ice trader

ice trader 33 minutes ago

This has dilution written all over it. Looks like we have to start treating the NASDAQ like the otc. Nothing trustworthy any more.

skitahoe

skitahoe 35 minutes ago

It's my belief that most of AVXL's trials do well, but not so well that the medical community quits looking for something better. My point is, AVXL is making small incremental improvements on several diseases, but it's not a magic bullet that will cure everything.

The good news is, i

axelvento

axelvento 35 minutes ago

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions